Kyntra Bio, Inc.
KYNB
$6.82
-$0.19-2.71%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 6.44M | 8.30M | 7.35M | 7.00M | 29.62M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.44M | 8.30M | 7.35M | 7.00M | 29.62M |
| Cost of Revenue | 24.07M | 38.65M | 57.40M | 83.95M | 132.35M |
| Gross Profit | -17.63M | -30.35M | -50.05M | -76.95M | -102.73M |
| SG&A Expenses | 27.71M | 28.80M | 32.87M | 40.72M | 49.33M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 51.78M | 67.45M | 90.27M | 124.67M | 181.68M |
| Operating Income | -45.34M | -59.16M | -82.92M | -117.67M | -152.06M |
| Income Before Tax | -58.30M | -52.35M | -87.49M | -121.09M | -153.37M |
| Income Tax Expenses | -90.00K | -88.00K | -85.00K | -274.00K | -269.00K |
| Earnings from Continuing Operations | -58.21 | -52.26 | -87.41 | -120.82 | -153.10 |
| Earnings from Discontinued Operations | 241.66M | 267.91M | 85.34M | 110.81M | 105.52M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 183.45M | 215.65M | -2.07M | -10.01M | -47.58M |
| EBIT | -45.34M | -59.16M | -82.92M | -117.67M | -152.06M |
| EBITDA | -44.59M | -58.06M | -81.29M | -115.47M | -149.37M |
| EPS Basic | 45.37 | 53.34 | -0.52 | -2.53 | -12.00 |
| Normalized Basic EPS | -7.91 | -10.13 | -13.74 | -19.09 | -24.25 |
| EPS Diluted | 45.37 | 53.34 | -0.52 | -2.53 | -12.00 |
| Normalized Diluted EPS | -7.91 | -10.13 | -13.74 | -19.09 | -24.25 |
| Average Basic Shares Outstanding | 16.17M | 16.16M | 16.13M | 16.09M | 16.01M |
| Average Diluted Shares Outstanding | 16.17M | 16.16M | 16.13M | 16.09M | 16.01M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |